Neary Catherine L, Nesterova Maria, Cho Yee Sook, Cheadle Chris, Becker Kevin G, Cho-Chung Yoon S
Cellular Biochemistry Section, Basic Research Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1750, USA.
Oncogene. 2004 Nov 18;23(54):8847-56. doi: 10.1038/sj.onc.1208165.
The cAMP-dependent protein kinase types I (PKA-I) and II (PKA-II), composed of identical catalytic (C) subunits but distinct regulatory (R) subunits (RI versus RII), are expressed in a balance of cell growth and differentiation. Distortion of this balance may underlie tumorigenesis and tumor growth. Here, we used PC3M prostate carcinoma cells as a model to overexpress wild type and mutant R and C subunit genes and examined the effects of differential expression of these genes on tumor growth. Only the RIIbeta and mutant RIalpha-P (a functional mimic of RIIbeta) transfectants exhibited growth inhibition in vitro, reverted phenotype, and apoptosis, and inhibited in vivo tumor growth. DNA microarrays demonstrated that RIIbeta and RIalpha-P overexpression upregulated a cluster of differentiation genes, while downregulating transformation and proliferation signatures. Overexpression of RIalpha and Calpha, which upregulated PKA-I, elicited the expression signatures opposite that elicited by RIIbeta overexpression. Total colocalization of Calpha and RIIbeta seen by confocal microscopy in the RIIbeta cell nucleus supports the opposed genomic regulation demonstrated between Calpha and RIIbeta cells. Differential expression of PKA R subunits may therefore serve as a tumor-target-based gene therapy for PC3M prostate and other cancers.
I型(PKA-I)和II型(PKA-II)环磷酸腺苷依赖性蛋白激酶由相同的催化(C)亚基和不同的调节(R)亚基(RI与RII)组成,它们在细胞生长和分化的平衡中表达。这种平衡的失调可能是肿瘤发生和肿瘤生长的基础。在这里,我们以PC3M前列腺癌细胞为模型,过表达野生型和突变型R和C亚基基因,并研究这些基因的差异表达对肿瘤生长的影响。只有RIIβ和突变型RIα-P(RIIβ的功能模拟物)转染子在体外表现出生长抑制、表型逆转和凋亡,并在体内抑制肿瘤生长。DNA微阵列显示,RIIβ和RIα-P的过表达上调了一组分化基因,同时下调了转化和增殖特征。RIα和Cα的过表达上调了PKA-I,引发了与RIIβ过表达相反的表达特征。共聚焦显微镜观察到Cα和RIIβ在RIIβ细胞核中完全共定位,这支持了Cα和RIIβ细胞之间显示的相反的基因组调控。因此,PKA R亚基的差异表达可能作为一种基于肿瘤靶点的基因疗法用于PC3M前列腺癌和其他癌症。